MedTrace Logo

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

NCT02322775 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2017-08-15

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of benralizumab across the spectrum of asthma disease.

Conditions

Interventions

BIOLOGICAL

Benralizumab

Benralizumab administered subcutaneously every 4 weeks

BIOLOGICAL

Placebo

Placebo administered subcutaneously every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Gary T. Ferguson, M.D.,P.C. · Pulmonary Research Institute of Southeast Michigan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-02
Primary Completion
2015-10-07
Completion
2015-10-07

Countries

  • United States
  • Canada
  • Germany
  • Hungary
  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322775 on ClinicalTrials.gov